A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors

Solid Tumor Clinical Trial

Official title:

Phase I Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05046847
• Other study ID #: TQB3811-I-01
• Status: Recruiting
• Phase: Phase 1
• Start date: November 30, 2021
• Est. completion date: December 2022

Study information

• Verified date: December 2021
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: LIN SHEN, Master
• Phone: 010-88196561
• Email: doctorshenlin[@]sina.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TQB3811 tablet is a second-generation tropomyosin receptor kinase (TRK) inhibitor that selectively inhibits the kinase activity of TRKA, TRKB, and TRKC, and also selectively inhibits the kinase activity of TRKA, TRKB, and TRKC that produce secondary drug-resistant mutations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2022
• Est. primary completion date: October 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with advanced malignancy diagnosed histologically and/or cytologically, who have failed standard treatment or are unable to receive standard treatment or have no effective treatment.
• Age: 18~75 years old.
• Women of childbearing age must be negative for serum or urine HCG within 7 days prior to study enrollment and must be non-lactating; Patients should agree to use contraception during the study period and for 6 months after the study period.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy = 3 months.
• Patients voluntarily joined the study and signed the informed consent, showing good compliance.

Exclusion Criteria:

• Patients has had or is currently having other malignant tumors within 3 years.
• Patients have multiple factors that affect their oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction).
• The patient had unmitigated toxic reactions due to any prior treatment.
• Patients underwent major surgical treatment, open biopsy, or significant traumatic injury within 4 weeks prior to the start of study treatment.
• Patients have long-term unhealed wounds or fractures.
• The patient had experienced an arterial/venous thrombosis event in the past 6 months, such as a cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis, and pulmonary embolism.
• The patient has a history of psychotropic drug abuse and cannot quit or has mental disorders.
• Patients are taking cytochrome P450 3A (CYP3A) inhibitors or inducers.
• Patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage.
• Patients with brain metastases with symptoms or control of symptoms for less than 2 weeks.
• The patients were currently breastfeeding or planned to breastfeed during the study period.
• Patients who, in the investigator's judgment, have a comorbidity that seriously endangers patient safety or interferes with study completion, or who are considered unsuitable for inclusion for other reasons

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• TQB3811
TQB3811 is a second-generation TrkA inhibitor.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	To evaluate MTD of TQB3811 tablets in Chinese adult patients with advanced solid tumors	Baseline up to 32 weeks
Primary	Adverse events (AEs) and serious adverse events (SAEs)	The occurrence of all AEs and SAEs	Baseline up to 28 days
Primary	Dose-limiting toxicity (DLT)	To evaluate DLT of TQB3811 tablets in Chinese adult patients with advanced solid tumors	Baseline up to 32 weeks
Secondary	Time to reach maximum (peak) plasma concentration following drug administration(Tmax)	To characterize the pharmacokinetics of TQB3811 by assessment of time to reach maximum plasma concentration after single and multiple dosing	15, 30minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11.
Secondary	Maximum (peak) plasma drug concentration (Cmax)	Cmax is the maximum plasma concentration of TQB3811 or metabolite(s).	15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 ;30 minutes before oral administration on day 1.
Secondary	Elimination half-life (t1/2)	t1/2 is time it takes for the blood concentration of TQB3811 or metabolite(s) to drop by half.	15, 30minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11.
Secondary	Area under the plasma concentration-time curve from time zero to time t (AUC0-t)	To characterize the pharmacokinetics of TQB3811 by assessment of area under the plasma concentration time curve from the first dose to infinity.	15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 ;30 minutes before oral administration on day 1.
Secondary	Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)	Cmax,ss is maximum (peak) steady-state plasma drug concentration during a dosage interval .	15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11.
Secondary	Minimum steady-state plasma drug concentration during a dosage interval (Css-min)	Css-min is minimum steady-state plasma drug concentration during a dosage interval.	15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11.
Secondary	Concentration at the end of the dosing interval (AUCtau,ss)	To characterize the pharmacokinetics of TQB3811 by assessment of area The concentration at the end of the administration interval	15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11.
Secondary	Progress Free Survival(PFS)	From the start of randomization to the first tumor progression or time of death.	up to 96 weeks
Secondary	Disease control rate(DCR)	Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).	up to 96 weeks
Secondary	Duration of Response (DOR)	The time when the participants first achieved complete or partial remission to disease progression.	up to 96 weeks